Eylea® Injection for Wet AMD and DME

Eylea is a prescription intravitreal medicine that blocks VEGF to manage certain retinal diseases. It is used by retina specialists to treat wet age-related macular degeneration and diabetic macular edema. This page explains indications, dosing basics, and access with US shipping from Canada, including options if you pay without insurance.

What Eylea Is and How It Works

CanadianInsulin connects patients with licensed Canadian pharmacies. Prescriptions are verified with your clinic before dispensing.

Eylea® contains aflibercept, a recombinant fusion protein that binds vascular endothelial growth factor (VEGF-A) and placental growth factor. By neutralizing these signals, the injection reduces abnormal vessel growth and fluid leakage in the retina. Ophthalmologists administer the dose into the vitreous under sterile conditions.

This treatment is approved for neovascular (wet) age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, and diabetic retinopathy. The exact visit cadence and monitoring plan are determined by your retina specialist according to the official labeling and exam findings.

Who It’s For

This medicine is used for adults with wet AMD. It also treats people with diabetic macular edema and macular edema after branch or central retinal vein occlusion. Many patients with diabetic retinopathy, with or without macular edema, may receive this therapy. Learn more about these conditions: Age Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy.

Avoid use if you have an active eye infection or significant ocular inflammation. People with a known serious hypersensitivity to aflibercept should not receive this medicine. Tell your clinician if you are pregnant, planning pregnancy, or nursing. Anti-VEGF agents can pose risks to a developing fetus, so timing and contraception deserve careful discussion.

Dosage and Usage

A retina specialist gives this injection in the office. The eye is cleaned with antiseptic, and a local anesthetic is used. Your clinician monitors intraocular pressure and vision after the procedure. Do not attempt self-injection or reuse any component.

Typical schedules follow the label for each condition. For wet AMD, many patients start with monthly injections for a period, then move to visits spaced farther apart. For diabetic macular edema, an initial series of monthly doses often precedes longer intervals. For macular edema after retinal vein occlusion, monthly treatment may continue until the disease is controlled. For diabetic retinopathy, dosing and monitoring are individualized per the label. Always follow your prescriber’s plan and the official Prescribing Information.

Strengths and Forms

The injection is supplied as single-use presentations, including a vial and a prefilled syringe. Each unit contains 2 mg/0.05 mL aflibercept intended for intravitreal use only. Availability can vary by presentation. Your clinician will specify the format that aligns with their technique and the labeled instructions.

Missed Dose and Timing

If you miss a scheduled appointment, contact your retina clinic as soon as possible. They will arrange the next appropriate visit and exam. Do not try to “double up” or change the plan on your own. Visual symptoms can fluctuate after a missed visit, so report any sudden changes, new floaters, flashes, or pain promptly.

Storage and Travel Basics

Store this medicine in a refrigerator in its original carton, protected from light. Do not freeze. Keep it out of children’s reach. Do not shake the vial or prefilled syringe. If you need to bring the product to your appointment, transport it in an insulated container with cool packs, avoiding direct contact with ice to prevent freezing. Keep the carton and labels intact for clinic verification.

When traveling, plan ahead with your clinic. Use a thermometer-equipped cooler when possible. Avoid leaving the package in a hot car or uncooled luggage. Carry your prescription details and clinic contact information. Airport screening staff may ask to see the label and your appointment note. Your clinic may prefer delivery directly to the office; confirm the process before shipping or travel.

Benefits

This therapy targets VEGF to reduce retinal fluid and leakage. Many patients experience stabilization of vision, and some may see improvement, depending on diagnosis and exam findings. After an initial phase, visit intervals can sometimes lengthen according to the label and clinician judgment. Clinic-based administration ensures sterile technique, pressure checks, and ongoing imaging to guide care.

Side Effects and Safety

• Eye discomfort or pain: usually mild and short-lived.
• Conjunctival redness or small hemorrhage: common after injections.
• Floaters or spots: may appear briefly after treatment.
• Temporary rise in eye pressure: monitored in the clinic.
• Cataract progression: can occur over time in some patients.
• Blurred vision: often transient after the procedure.

Serious but less common risks include endophthalmitis, retinal detachment or tear, significant inflammation, sustained pressure elevation, and arterial thromboembolic events such as stroke. Seek urgent care for severe eye pain, worsening redness, light sensitivity, sudden vision loss, increasing floaters, or flashes. People with active ocular infection or severe inflammation should defer injections until cleared by a clinician.

Drug Interactions and Cautions

Systemic exposure is low, so traditional drug–drug interactions are uncommon. However, tell your clinician about all medicines you take, including antiplatelet or anticoagulant therapy, since ocular bleeding can occur after injections. Report any history of stroke or transient ischemic attack. Use caution in pregnancy, and discuss contraception if you are of childbearing potential. If you develop fever, eyelid swelling, or new redness around the eye, inform the clinic before your next visit. For background reading on eye complications in diabetes, see Managing Retinopathy and Diabetic Eye Disease.

What to Expect Over Time

Most treatment courses start with closer monitoring to control fluid and stabilize vision. Imaging such as OCT helps your clinician track changes and adjust visit intervals. Some people can transition to less frequent dosing after the initial phase, while others need ongoing monthly care. Consistent follow-up and symptom reporting are important. If changes occur between visits, call the clinic rather than waiting for the next appointment.

Compare With Alternatives

Other anti‑VEGF options include ranibizumab and brolucizumab. Depending on your diagnosis and exam, a clinician may consider alternatives. For product details, review Lucentis® Prefilled Syringe and Beovu® Pre Filled Syringe. Dosing intervals, preparation steps, and safety profiles differ by product and indication. Your retina specialist will outline the approach that fits your eye condition.

If disease control remains suboptimal or intolerable effects occur, clinicians may switch therapies or adjust intervals in line with labeling and clinical judgment. Imaging and visual function guide these decisions. Ask your prescriber about the reasoning behind your specific plan.

Pricing and Access

CanadianInsulin lists transparent pricing for clinic-dispensed eye treatments. Review current options, check availability, and compare typical cash-pay approaches. If you are exploring Eylea 2 mg for your treatment plan, you can view current pricing before you order. For potential savings and seasonal offers, see Promotions. Orders are processed through licensed Canadian pharmacies, with secure, encrypted checkout. Your prescription is required and will be verified with your clinic. Canadian pricing is available to US patients, and your care team can direct delivery as appropriate.

Availability and Substitutions

Supply can vary by vial or prefilled syringe. If a presentation is unavailable, your prescriber may recommend an appropriate alternative or adjust the format. Your clinic will determine whether a substitution meets your medical needs and aligns with the label.

Patient Suitability and Cost-Saving Tips

Candidates include adults with wet AMD, diabetic macular edema, macular edema after retinal vein occlusion, or diabetic retinopathy, as determined by a clinician. People with active eye infections, severe inflammation, or known hypersensitivity to components should avoid treatment. To manage costs, ask your clinic about scheduling refills ahead of appointments, coordinating multi-visit planning, and setting reminders so injections and deliveries stay aligned. Bringing the product directly to the clinic on the day of treatment can reduce the risk of waste from missed visits.

Questions to Ask Your Clinician

• My diagnosis and goals: what are we aiming to improve?
• Visit frequency: how often will I need exams and injections?
• Monitoring plan: which tests guide decisions between visits?
• Safety monitoring: which warning signs require immediate contact?
• Format choice: vial or prefilled syringe for my clinic workflow?
• Travel and storage: how should I transport and store the product?
• Alternatives: when might another anti‑VEGF be considered?

Authoritative Sources

Manufacturer Prescribing InformationFDA DailyMedHealth Canada DPD

Ready to proceed? Start your order with prompt, express, cold-chain shipping and US shipping from Canada. This content is educational and does not replace your clinician’s advice or the official label.